Novo Nordisk is raising the stakes in its push to outbid rival Pfizer and acquire the development-stage drugmaker Metsera. Novo is now offering to pay as much as $10 billion for the company, Metsera said Tuesday. That's higher than its previous bid of up to $9 billion which sparked a lawsuit from Pfizer. Pfizer also [...]

See Full Page